At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PROK ProKidney Corp.
Trading 11-12 14:48:07 EST
1.14
+0.01
+0.44%
High1.18Low1.08Vol896.59K
Open1.12D1 Closing1.13Amplitude8.85%
Mkt Cap343.14MTradable Cap208.84MTotal Shares302.32M
T/O1.01MT/O Rate0.49%Tradable Shares184.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Prokidney Corp Enters Open Market Sale Agreement with Jefferies
Reuters  ·  10-30
Prokidney Corp Enters Open Market Sale Agreement with Jefferies
ProKidney Signs Agreement with Jefferies for up to $200 Million At-the-Market Share Offering
Reuters  ·  10-30
ProKidney Signs Agreement with Jefferies for up to $200 Million At-the-Market Share Offering
ProKidney Corp - Jefferies Entitled to up to 3.0% of Gross Offering Proceeds - SEC Filing
THOMSON REUTERS  ·  10-30
ProKidney Corp - Jefferies Entitled to up to 3.0% of Gross Offering Proceeds - SEC Filing
ProKidney Corp - Enters Open Market Sale Agreement with Jefferies on Oct 29, 2026 - SEC Filing
THOMSON REUTERS  ·  10-30
ProKidney Corp - Enters Open Market Sale Agreement with Jefferies on Oct 29, 2026 - SEC Filing
ProKidney Corp - May Offer Shares up to $200 Mln Aggregate Offering Price Under Sales Agreement - SEC Filing
THOMSON REUTERS  ·  10-30
ProKidney Corp - May Offer Shares up to $200 Mln Aggregate Offering Price Under Sales Agreement - SEC Filing
ProKidney Corp - May Offer up to $650 Mln of Securities in Aggregate - SEC Filing
THOMSON REUTERS  ·  10-30
ProKidney Corp - May Offer up to $650 Mln of Securities in Aggregate - SEC Filing
Analysts Are Bullish on Top Healthcare Stocks: Precision BioSciences (DTIL), ProKidney (PROK)
TIPRANKS  ·  10-29
Analysts Are Bullish on Top Healthcare Stocks: Precision BioSciences (DTIL), ProKidney (PROK)
ProKidney Price Target Cut to $8.00/Share from $10.00 by Citigroup
Dow Jones  ·  10-29
ProKidney Price Target Cut to $8.00/Share from $10.00 by Citigroup
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Beam Therapeutics (BEAM) and ProKidney (PROK)
TIPRANKS  ·  10-28
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Beam Therapeutics (BEAM) and ProKidney (PROK)
ProKidney Presents Rilparencel Mechanism-of-Action Findings in Advanced Kidney Disease
Reuters  ·  10-27
ProKidney Presents Rilparencel Mechanism-of-Action Findings in Advanced Kidney Disease
ProKidney Hosts KOL Event to Review Rilparencel Mechanism of Action Data
Reuters  ·  10-22
ProKidney Hosts KOL Event to Review Rilparencel Mechanism of Action Data
ProKidney to Host Virtual Kol Event to Recap Mechanism of Action Data Presented at Asn Kidney Week and Provide a Corporate Update
THOMSON REUTERS  ·  10-22
ProKidney to Host Virtual Kol Event to Recap Mechanism of Action Data Presented at Asn Kidney Week and Provide a Corporate Update
ProKidney Pooled Phase 2 Analysis Indicates Kidney Function Stabilization in Advanced CKD Patients
Reuters  ·  10-22
ProKidney Pooled Phase 2 Analysis Indicates Kidney Function Stabilization in Advanced CKD Patients
Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Roivant Sciences (ROIV)
TIPRANKS  ·  10-12
Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Roivant Sciences (ROIV)
ProKidney Posts Pooled Phase 2 Data Showing Rilparencel Stabilizes Kidney Function in Advanced CKD with Diabetes
Reuters  ·  10-02
ProKidney Posts Pooled Phase 2 Data Showing Rilparencel Stabilizes Kidney Function in Advanced CKD with Diabetes
ProKidney Director Brian JG Pereira Sells USD 1.06 Million in Common Shares
Reuters  ·  08-21
ProKidney Director Brian JG Pereira Sells USD 1.06 Million in Common Shares
Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes
Reuters  ·  08-14
Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)
TIPRANKS  ·  08-13
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)
MiNK Therapeutics Q2 Loss Narrows on Expense Discipline
Reuters  ·  08-13
MiNK Therapeutics Q2 Loss Narrows on Expense Discipline
MaxCyte Q2 Revenue Beats Estimates
Reuters  ·  08-13
MaxCyte Q2 Revenue Beats Estimates

Introduction

Company Name.
ProKidney Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Issue price:
--